Urs Langen

Company: Roche

Job title: Lab Head

Seminars:

Innovating Second Generation Antibodies Targeting Toxic Proteinopathies with Enhanced Blood-Brain Barrier Penetrance 3:30 pm

Reviewing the latest progress of shuttling technologies to enhance therapeutic targeting to the brain and reduce side effects like ARIA Investigating mechanisms of transport across the BBB to uncover opportunities to more effectively target neurodegenerative protein aggregates Widening the cargo space of antibody brain shuttles; what other modalities can be applied?Read more

day: Conference Day Two PM